Clinical trials: Allergy, Peanut

Peanut Allergy

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

• Completed
• Age: 18 to 55 years
• Phase 1
• Injection or infusion

The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal or intramuscular injection in adults with peanut allergy.

Trial name

NCT02851277

Testing

ASP0892 Intradermal, ASP0892 Intramuscular

Where

8 sites in United States

Volunteers

31 people

Sponsor

Astellas Pharma Global Development, Inc.